Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 12/20 | 0.72 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576905 | 1.00 | AGER (0.72) | AGERCDK4CDK2ALDH1A1HPGD | |
| SCHEMBL1576892 | 1.00 | AGER (0.72) | AGERCDK4CDK2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL1889347 | 0.99 | AGER (0.71) | AGERCDK4CDK2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL1893690 | 0.99 | AGER (0.71) | AGERCDK4CDK2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL1889343 | 0.99 | AGER (0.71) | AGERCDK4CDK2ALDH1A1HPGD | |
| SCHEMBL1890014 | 0.93 | AGER (0.75) | AGERSLC6A4 | |
| SCHEMBL1577018 | 0.93 | AGER (0.75) | AGERSLC6A4 | |
| SCHEMBL1577020 | 0.93 | AGER (0.75) | AGERSLC6A4 | |
| Hydrochloric Acid SCHEMBL1889808 | 0.92 | AGER (0.73) | AGERSLC6A4 | |
| Hydrochloric Acid SCHEMBL1888277 | 0.92 | AGER (0.73) | AGERSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | claimed |
| US-9598375-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2017-03-21 | — | — | US | claimed |
| EP-2470510-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMERS DISEASE. | TRANSTECH PHARMA LLC (US) | 2014-05-14 | — | — | EP | claimed |
| US-20140039025-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2014-02-06 | — | — | US | claimed |
| US-8580833-B2 | Substituted imidazole derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-11-12 | — | — | US | claimed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | claimed |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | disclosed |
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | VTV THERAPEUTICS LLC | 2017-06-08 | — | — | US | disclosed |
| US-8580833-B2 | Substituted imidazole derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580833-B2 | Substituted imidazole derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580833-B2 | Substituted imidazole derivatives and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | VTV THERAPEUTICS LLC | 2011-05-05 | — | — | US | disclosed |
| WO-2011041198-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMERS DISEASE | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157093-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP11B2, CYP2C19, SLC10A2 | AGER 1632/4885CDK4 2619/4885CDK2 2378/4885 |
| US-20140039025-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | MAPT, PSEN2, PSEN1 | AGER 371/4885CDK4 2745/4885CDK2 2459/4885 |
| US-20190076402-A1 | Substituted Imidazole Derivatives and Methods of Use Thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885CDK4 1658/4885CDK2 1035/4885 |
| US-10363241-B2 | Substituted imidazole derivatives and methods of use thereof | CYP3A7, CYP3A5, CYP3A43 | AGER 3594/4885CDK4 1658/4885CDK2 1035/4885 |
| US-20110105578-A1 | Substituted Imidazole Derivatives And Methods Of Use Thereof | AGER, NOD2, PSEN1 | AGER 1/4885CDK4 3078/4885CDK2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.